Disagee with your money blowing comment. When the 2020Vision was still in place, acquisition was on the table. Yet, they were hoarding cash.
Andrew was also addressing possible acquisitions which would only be in the radiotherapy field. Again, this has shown the management wasn’t blowing money anyway to buy growth.
The 30mill buy back program would have started early if it wasn’t for the court issues.
If BTG could still grow its sales, it meant the techinolgy itself wasn’t going to be obsolete due to the new alternative therapy.
SRX Price at posting:
$13.61 Sentiment: Buy Disclosure: Held